Neuroendocrine Tumors Pipeline Assessment, 2023 Updates: FDA, EMA, and PMDA Approvals, Emerging Drugs, Clinical Trials, Therapeutic Analysis, and Growth Prospects | Eli Lilly and Company, Teclison

The Neuroendocrine Tumors Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

“Neuroendocrine Tumors Pipeline Insight, 2023“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Neuroendocrine Tumors Market.

Some of the key takeaways from the Neuroendocrine Tumors Pipeline Report:

• Companies across the globe are diligently working toward developing novel Neuroendocrine Tumors treatment therapies with a considerable amount of success over the years. 
• Neuroendocrine Tumors companies working in the treatment market are Panavance Therapeutics, Nano Pharmaceuticals, Oxford BioTherapeutics, Immunomic Therapeutics, Crinetics Pharmaceuticals, Biotheus, Seneca Therapeutics, Amgen, POINT Biopharma, RayzeBio, Radiomedix, Inc/Orano Med LLC,  Molecular Targeting Technologies, Inc., Viewpoint Molecular Targeting, Exelixis, Eli Lilly and Company, Teclison Ltd., Novatek Pharmaceuticals, Phanes Therapeutics, Camurus AB, Hutchmed, Merck Sharp & Dohme LLC, BioXcel Therapeutics Inc, Boehringer Ingelheim, Vyriad, Inc., Hoffmann-La Roche, Monte Rosa Therapeutics, Inc, Amgen, ORIC Pharmaceuticals, and others, are developing therapies for the Neuroendocrine Tumors treatment 

• Emerging Neuroendocrine Tumors therapies in the different phases of clinical trials are- GP-2250, BG-P-TAT, OBT-620, ITI 3000, Paltusotine, PM8002, SVV-001, Tarlatamab, PNT2003, RYZ101, AlphaMedix, 177Lu-DOTA-EB-TATE, [212Pb]VMT-α-NET, Lu-177, Abemaciclib, Tirapazamine, NP-101, PT217, CAM2029, Surufatinib, Belzutifan, BXCL701 plus Pembrolizumab, BI 764532, VSV-IFNβ-NIS, RO7616789, Oral MRT-2359, Tarlatamab, ORIC-944, and others are expected to have a significant impact on the Neuroendocrine Tumors market in the coming years.  
• In October 2023, Two upcoming investigator-initiated trials (IIT) were presented at the North American Neuroendocrine Tumour Society (NANETS) 2023 Symposium in Montreal, Canada, which was held October 4-6, 2023, according to a press release from Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX).
• In September 2023, Lutathera® (INN: lutetium (177Lu) oxodotreotide / USAN: lutetium Lu 177 dotatate), according to Novartis, achieved its primary endpoint in the Phase III NETTER-2 trial. In comparison to high-dose long-acting octreotide alone, first-line treatment with Lutathera and long-acting octreotide showed a significant improvement in progression-free survival (PFS) in patients with newly diagnosed Grade 2 and 3 advanced gastroenteropancreatic neuroendocrine tumours (GEP-NETs) that express the somatostatin receptor (SSTR)1,2. The study did not reveal any novel or unexpected safety results, and the data are consistent with Lutathera1-4’s well-known safety profile.
• In May 2023, Amgen initiated a randomized, open-label, Phase III study of tarlatamab compared withstandard of care in subjects with relapsed small cell lung cancer after platinum-based first-line chemotherapy. The trial is currently recruiting the participants and is expected to be completed by June 2025, with an estimated enrollment of 700 participants. 

Neuroendocrine Tumors Overview

The specialised cells of the body’s neuroendocrine system are where a neuroendocrine cancer, also known as a neuroendocrine tumour (NET) or neuroendocrine neoplasm, starts. These cells have characteristics of both nerve cells and hormone-producing endocrine cells.They can be present in all of the body’s organs and are involved in various bodily processes.

Get a Free Sample PDF Report to know more about Neuroendocrine Tumors Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/neuroendocrine-tumors-pipeline-insight

Emerging Neuroendocrine Tumors Drugs Under Different Phases of Clinical Development Include:

• GP-2250: Panavance Therapeutics
• BG-P-TAT: NanoPharmaceuticals
• OBT-620: Oxford BioTherapeutics
• ITI 3000: Immunomic Therapeutics
• Paltusotine: Crinetics Pharmaceuticals
• PM8002: Biotheus
• SVV-001: Seneca Therapeutics
• Tarlatamab: Amgen
• PNT2003: POINT Biopharma
• RYZ101: RayzeBio
• AlphaMedix: Radiomedix, Inc/Orano Med LLC
• 177Lu-DOTA-EB-TATE: Molecular Targeting Technologies, Inc.
• [212Pb]VMT-α-NET: Viewpoint Molecular Targeting
• Lu-177: Exelixis
• Abemaciclib: Eli Lilly and Company
• Tirapazamine: Teclison Ltd.
• NP-101: Novatek Pharmaceuticals
• PT217: Phanes Therapeutics
• CAM2029: Camurus AB
• Surufatinib: Hutchmed
• Belzutifan: Merck Sharp & Dohme LLC
• BXCL701 plus Pembrolizumab: BioXcel Therapeutics Inc
• BI 764532: Boehringer Ingelheim
• VSV-IFNβ-NIS: Vyriad, Inc.
• RO7616789: Hoffmann-La Roche
• Oral MRT-2359: Monte Rosa Therapeutics, Inc
• Tarlatamab: Amgen
• ORIC-944: ORIC Pharmaceuticals

Neuroendocrine Tumors Route of Administration

Neuroendocrine Tumors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical

Neuroendocrine Tumors Molecule Type

Neuroendocrine Tumors Products have been categorized under various Molecule types, such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy 

Neuroendocrine Tumors Pipeline Therapeutics Assessment

• Neuroendocrine Tumors Assessment by Product Type
• Neuroendocrine Tumors By Stage and Product Type
• Neuroendocrine Tumors Assessment by Route of Administration
• Neuroendocrine Tumors By Stage and Route of Administration
• Neuroendocrine Tumors Assessment by Molecule Type
• Neuroendocrine Tumors by Stage and Molecule Type

DelveInsight’s Neuroendocrine Tumors Report covers around 60+ products under different phases of clinical development like

• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Neuroendocrine Tumors product details are provided in the report. Download the Neuroendocrine Tumors pipeline report to learn more about the emerging Neuroendocrine Tumors therapies

Some of the key companies in the Neuroendocrine Tumors Therapeutics Market include:

Key companies developing therapies for Neuroendocrine Tumors are – Radiomedix, Inc, Orano Med LLC, Molecular Targeting Technologies, Inc., Viewpoint Molecular Targeting, Exelixis, Eli Lilly and Company, Teclison Ltd., Novatek Pharmaceuticals, Phanes Therapeutics, Camurus AB, Hutchmed, Merck Sharp & Dohme LLC, BioXcel Therapeutics Inc, Boehringer Ingelheim, RayzeBio, Inc., Vyriad, Inc., Hoffmann-La Roche, Monte Rosa Therapeutics, Inc, Amgen, ORIC Pharmaceuticals, and others.

Neuroendocrine Tumors Pipeline Analysis:

The Neuroendocrine Tumors pipeline report provides insights into 

• The report provides detailed insights about companies that are developing therapies for the treatment of Neuroendocrine Tumors with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Neuroendocrine Tumors Treatment.
• Neuroendocrine Tumors key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Neuroendocrine Tumors Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Neuroendocrine Tumors market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Neuroendocrine Tumors drugs and therapies

Neuroendocrine Tumors Pipeline Market Drivers

• Rising prevalence of the disease, growing Research and Development Activities are some of the important factors that are fueling the Neuroendocrine Tumors Market.

Neuroendocrine Tumors Pipeline Market Barriers

• However, limited Awareness and under diagnosis, heterogeneity and Complexity and other factors are creating obstacles in the Neuroendocrine Tumors Market growth.

Scope of Neuroendocrine Tumors Pipeline Drug Insight    

• Coverage: Global
• Key Neuroendocrine Tumors Companies: Panavance Therapeutics, Nano Pharmaceuticals, Oxford BioTherapeutics, Immunomic Therapeutics, Crinetics Pharmaceuticals, Biotheus, Seneca Therapeutics, Amgen, POINT Biopharma, RayzeBio, Radiomedix, Inc/Orano Med LLC,  Molecular Targeting Technologies, Inc., Viewpoint Molecular Targeting, Exelixis, Eli Lilly and Company, Teclison Ltd., Novatek Pharmaceuticals, Phanes Therapeutics, Camurus AB, Hutchmed, Merck Sharp & Dohme LLC, BioXcel Therapeutics Inc, Boehringer Ingelheim, Vyriad, Inc., Hoffmann-La Roche, Monte Rosa Therapeutics, Inc, Amgen, ORIC Pharmaceuticals, and others
• Key Neuroendocrine Tumors Therapies: GP-2250, BG-P-TAT, OBT-620, ITI 3000, Paltusotine, PM8002, SVV-001, Tarlatamab, PNT2003, RYZ101, AlphaMedix, 177Lu-DOTA-EB-TATE, [212Pb]VMT-α-NET, Lu-177, Abemaciclib, Tirapazamine, NP-101, PT217, CAM2029, Surufatinib, Belzutifan, BXCL701 plus Pembrolizumab, BI 764532, VSV-IFNβ-NIS, RO7616789, Oral MRT-2359, Tarlatamab, ORIC-944, and others
• Neuroendocrine Tumors Therapeutic Assessment: Neuroendocrine Tumors current marketed and Neuroendocrine Tumors emerging therapies
• Neuroendocrine Tumors Market Dynamics: Neuroendocrine Tumors market drivers and Neuroendocrine Tumors market barriers 

Request for Sample PDF Report for Neuroendocrine Tumors Pipeline Assessment and clinical trials

Table of Contents 

1. Neuroendocrine Tumors Report Introduction

2. Neuroendocrine Tumors Executive Summary

3. Neuroendocrine Tumors Overview

4. Neuroendocrine Tumors- Analytical Perspective In-depth Commercial Assessment

5. Neuroendocrine Tumors Pipeline Therapeutics

6. Neuroendocrine Tumors Late Stage Products (Phase II/III)

7. Neuroendocrine Tumors Mid Stage Products (Phase II)

8. Neuroendocrine Tumors Early Stage Products (Phase I)

9. Neuroendocrine Tumors Preclinical Stage Products

10. Neuroendocrine Tumors Therapeutics Assessment

11. Neuroendocrine Tumors Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Neuroendocrine Tumors Key Companies

14. Neuroendocrine Tumors Key Products

15. Neuroendocrine Tumors Unmet Needs

16 . Neuroendocrine Tumors Market Drivers and Barriers

17. Neuroendocrine Tumors Future Perspectives and Conclusion

18. Neuroendocrine Tumors Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: 8774225362
Address:27 Drydock Ave S. Jones Blvd #2432
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services